Cefotaxim-natrium
ctx · CEFOTAXIME SODIUM STERILE · CEFOTAXIME SODIUM SALT · CLAFORAN · Sodium cefotaxime · CEFOTAXIME NA-SALT · Cefotaxime free acid · CEFOTAXIM SODIUM SALT
Identifikatoren & physikalische Daten
| CAS No. | 64485-93-4 |
|---|---|
| Summenformel | C16H16N5NaO7S2 |
| Durchschnittliche Molmasse | 477,5 g/mol |
| Monoisotopische Masse | 477,03888413 g/mol |
| SMILES | CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(C)=O)CS[C@H]12)c1csc(N)n1.[Na+] |
| InChIKey | AZZMGZXNTDTSME-JUZDKLSSSA-M |
| PubChem CID | 10695961 |
| ChEMBL | CHEMBL1010 |
| ChEBI | CHEBI:3498 |
| EC No. | 264-915-9 |
| DTXSID | DTXSID4046991 |
| Lokaler Name | Cefotaxim-natrium |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 230 |
|---|---|
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 12 |
| Frei drehbare Bindungen | 8 |
| Schwere Atome | 31 |
| Formalladung | 0 |
| Komplexität | 839 |
| Löslichkeit | 68.2 [ug/mL] (The mean of the results at pH 7.4)H2O: aqueous solutions of pH 4.3-6.2 are stable up to 3 weeks at 2-8 °C.solubleSoluble in water. |
| Human Drugs | FDA approved drugs -> Active ingredient |
| Schmelzpunkt | 162-163 C |
| Brechungsindex | 61 ° (C=1, H2O) |
| Lagerbedingungen | Keep in dark place,Inert atmosphere,2-8°C |
| Aggregatzustand | powder |
| Farbe | white to yellow |
| pH | pH(100g/l, 25℃) : 4.5～6.5 |
| Merck | 14,1933 |
| BRN | 5711411 |
| Stabilität | Stable. Incompatible with strong oxidizing agents. |
| InChIKey | ACGQSCNTUWPWNB-RRVHIMMXNA-N |
| SMILES | C(C1=C(CS[C@]2([H])[C@H](NC(=O)/C(/C3=CSC(N)=N3)=N\OC)C(=O)N12)COC(=O)C)(=O)O.[NaH] |&1:5,7,r| |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH317 (99.2%): May cause an allergic skin reaction [Warning Sensitization, Skin]P233, P260, P261, P271, P272, P280, P284, P302+P352, P304+P340, P321, P333+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 132 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Regulatorische Informationen | Cefotaxime sodium: Does not have an individual approval but may be used under an appropriate group standard |
| Hazard Classes and Categories | Skin Sens. 1 (99.2%) |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Cefotaxime sodiumvLess-DILI-concern5Adverse reactionsDOI:10.1016/j.drudis.2016.02.015 |
| Wassergefährdungsklasse (WGK) | 2 |
| Zollcode | 29419000 |
| RTECS-Nr. | XI0250000 |
| R-Sätze (R) | 42/43 |
| Gefahrensymbole | Xn,Xi |
| Sicherheitshinweise (S) | 22-36/37-60-45-37-24 |
| Lagerklasse | 11 - Combustible Solids |
| Gefahrenklasse | Resp. Sens. 1Skin Sens. 1 |
Anwendungen & Verwendung
Beschreibung
Cefotaxime was synthesized by Hoechst and Roussel-Uclaf in 1977. It was the first derivative of cephalosporin to introduce the methoxyimino and aminothiazole groups at the 7 position of the cephem nucleus. Although it shows unexpectedly low oral absorption, its excellent activity against a wide range of gram-positive and gram-negative organisms, including Serratia, Enterobacter, Citrobacter, and anaerobes, guided research and development of the newer synthetic cephems, the so-called thirdgeneration cephalosporins.
Verwenden
Cefotaxime sodium salt acts as a beta-lactamase resistant antibiotic. It is used as an effective antibacterial against gram-negative bacteria, with the notable exception of pseudomonas and penicillin-resistant strains of streptococcus pneumoniae. It is used to treat infections of the bones, joints, skin, respiratory tract and blood stream.